F598

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
F598

GtoPdb Ligand ID: 13554

Synonyms: SAR279356

Compound class: Antibody

Comment: F598 is a fully human IgG1 monoclonal antibody that targets poly-β-1,6-N-acetyl-d-glucosamine (PNAG) in microbial surfaces and biofilms [1-3]. It is being developed by Alopexx Pharma (Cambridge, USA) as an immune-mediated therapy for the prevention of nosocomial infections.

No information available.

No information available.

Summary of Clinical Use
F598 progressed to Phase 2 evaluation, hovever both registered trials have been terminated (see table below for details). Development of F598 appears to be active as it is listed in Alopexx Pharma's development pipeline (September, 2024).

Summary of Clinical Use

F598 progressed to Phase 2 evaluation, hovever both registered trials have been terminated (see table below for details). Development of F598 appears to be active as it is listed in Alopexx Pharma's development pipeline (September, 2024).

Mechanism Of Action and Pharmacodynamic Effects
F598 targets PNAG, a polysaccharide that is highly conserved and expressed on the surface of many microorganisms, including Gram-negative and Gram-positive bacteria, fungi, and protozoan parasites but is not found in mammals [1].

Mechanism Of Action and Pharmacodynamic Effects

F598 targets PNAG, a polysaccharide that is highly conserved and expressed on the surface of many microorganisms, including Gram-negative and Gram-positive bacteria, fungi, and protozoan parasites but is not found in mammals [1].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT03222401	Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males	Phase 2 Interventional	AlopexxPharma	Terminated following interim analysis that suggested that the study, as designed, was not adequately powered to detect a therapeutic effect.
NCT01389700	Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients	Phase 2 Interventional	Sanofi	Terminated due to difficulty in patient recruitment.